HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supply Of 'Important' OTCs From EU Prioritized In Event Of No Deal Brexit

Executive Summary

In preparation for a possible no deal Brexit, the UK government is prioritizing supply from the EU those OTC medicines deemed "important for the management of specific health conditions." The Department of Health and Social Care says it is continuing to work closely with OTC manufacturers and suppliers to prepare for Brexit.

You may also be interested in...



Future Still Looking Bright For UK Switch, Even After Brexit – Q&A With PAGB's Michelle Riddalls

The UK has for decades been considered a European Rx-to-OTC switch leader. A combination of regulatory openness and a strong retail infrastructure will enable the country to remain so even if it leaves the European Union in October, insists the Proprietary Association of Great Britain's senior director of Regulatory Affairs, Michelle Riddalls, in an exclusive interview.

Supplement Firms Face Spiralling Costs And Serious Disruption In Event Of No Deal Brexit

Labelling costs approaching £1.0m, import and export delays, and higher consumer prices are some of the many issues facing the food supplements industry in the event of a no deal Brexit, trade association CRN UK tells HBW Insight.

UK To Overhaul Health Claims Approval In Event of 'No Deal' Brexit

In the event of a no deal Brexit, new health claims approved by EFSA will not be valid in the UK. Firms will need to seek approval from the new UKNHCC body.

Related Content

Topics

UsernamePublicRestriction

Register

RS148573

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel